Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective

Overview of attention for article published in BioDrugs, August 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#34 of 756)
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 2 news outlets

twitter: 6 X users

Readers on

mendeley: 18 Mendeley

Summary News X

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 40,786 followers.

RT @SamsungBioepis: What do four executives of global pharmaceutical companies suggest for the future of #biosimilars? Co-authors of an ar…

29 Aug 2023

Reply Repost Favourite

What do four executives of global pharmaceutical companies suggest for the future of #biosimilars? Co-authors of an article in BioDrugs—including Samsung Bioepis' VP Gillian Woollett—point to streamlining biosimilar development. Read the full article:

29 Aug 2023

Reply Repost Favourite

RT @USBiosimilars: NEW: A peer-reviewed scientific publication from the Biosimilars Forum provides comprehensive recommendations on how bio…

07 Aug 2023

Reply Repost Favourite

NEW: A peer-reviewed scientific publication from the Biosimilars Forum provides comprehensive recommendations on how biosimilar development should evolve. Read the full manuscript in @BioDrugsJournal here: https://t.co/tYH9L4AX8z

07 Aug 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.